Shanxi unveils development plan for pharmaceutical industry

North China's Shanxi province has released the "Medium to Long-Term Development Plan for the Modern Pharmaceutical Industry Chain (2024-2026)", aiming to attract over 120 enterprises in the modern pharmaceutical industry chain by 2026, with an annual revenue exceeding 66 billion yuan ($9.28 billion).

The plan will implement the "chain leader system", expanding enterprises within the industry chain and advancing industrial parks and project construction. It aims to promote intelligent, green, and service-oriented industrial development and achieve the coordinated development of traditional Chinese medicine (TCM) and Western medicine.

The plan also focuses on optimizing business environments and improving the industry chain to enhance competitiveness. This will drive high-quality development of the modern pharmaceutical industry, improve public health, and support the comprehensive construction of a healthy Shanxi.

The plan's goals include standardizing TCM production, improving TCM quality, building an industrial structure in pharmaceutical manufacturing, and accelerating technological innovation and industrial upgrades. 

The scale of the TCM health, pharmaceutical packaging materials, and medical device industries should achieve significant growth, which will provide strong support for manufacturing. 

Furthermore, the plan encourages innovative pharmaceutical distribution models that foster a healthier competitive market landscape and promote steady profit growth in Shanxi's modern pharmaceutical industry chain.